Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients

M. L. Lu, H. Y. Lane, K. P. Chen, M. W. Jann, M. H. Su, W. H. Chang

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Background: Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia. Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2. We evaluated the safety and efficacy of fluvoxamine, 50 mg/day, coadministration with clozapine, 100 mg/day, in refractory schizophrenic patients. Method: In this prospective study, 18 treatment-refractory patients with DSM-IV schizophrenia (10 nonsmokers and 8 smokers) were treated with cloza-pine at a target dose of 100 mg h.s. After steady-state conditions of clozapine had been reached, 50 mg/day of fluvoxamine was then added. Plasma levels of clozapine, norclozapine, and clozapine N-oxide were measured prior to fluvoxamine addition and on days 14 and 28 during combined treatment. Side effects and efficacy were monitored with standardized rating instruments. Results: After 14 days of combined treatment, the mean ± SD plasma clozapine level increased 2.3-fold to 432.4 ± 190.9 ng/mL without further elevation on day 28. All patients completed the study without significant adverse side effects. Twelve of the 18 patients achieved plasma clozapine concentrations of at least 350 ng/mL. While plasma norclozapine levels also rose (but to a smaller extent), plasma clozapine N-oxide levels remained unchanged after the add-on therapy. Patients who smoked had 34% lower plasma clozapine concentrations than nonsmokers (NS). Three of the 4 patients who did not reach clozapine plasma levels of at least 300 ng/mL were smokers. Plasma norclozapine/clozapine ratios, especially in smokers, declined significantly with fluvoxamine addition. Conclusion: The addition of fluvoxamine, 50 mg/day, to low-dose clozapine, 100 mg/day, can raise plasma clozapine levels to at least 300 ng/mL in most patients. Only slight dosage adjustments with clozapine may be needed after fluvoxamine coadministration in some patients who smoke. Plasma clozapine levels remained stable after 14 days of fluvoxamine addition. The combined treatment was well tolerated, and clinical improvement was observed in our patients. Further long-term studies with this drug combination are needed to determine its economic impact.

Original languageEnglish
Pages (from-to)594-599
Number of pages6
JournalJournal of Clinical Psychiatry
Volume61
Issue number8
Publication statusPublished - 2000
Externally publishedYes

Fingerprint

Fluvoxamine
Clozapine
norclozapine
Schizophrenia
Therapeutics
Social Adjustment
Cytochrome P-450 CYP1A2
Drug Combinations
Smoke
Diagnostic and Statistical Manual of Mental Disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Lu, M. L., Lane, H. Y., Chen, K. P., Jann, M. W., Su, M. H., & Chang, W. H. (2000). Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. Journal of Clinical Psychiatry, 61(8), 594-599.

Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. / Lu, M. L.; Lane, H. Y.; Chen, K. P.; Jann, M. W.; Su, M. H.; Chang, W. H.

In: Journal of Clinical Psychiatry, Vol. 61, No. 8, 2000, p. 594-599.

Research output: Contribution to journalArticle

Lu, ML, Lane, HY, Chen, KP, Jann, MW, Su, MH & Chang, WH 2000, 'Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients', Journal of Clinical Psychiatry, vol. 61, no. 8, pp. 594-599.
Lu, M. L. ; Lane, H. Y. ; Chen, K. P. ; Jann, M. W. ; Su, M. H. ; Chang, W. H. / Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients. In: Journal of Clinical Psychiatry. 2000 ; Vol. 61, No. 8. pp. 594-599.
@article{83d68a86c84a437bad3dc492c180c35c,
title = "Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients",
abstract = "Background: Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia. Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2. We evaluated the safety and efficacy of fluvoxamine, 50 mg/day, coadministration with clozapine, 100 mg/day, in refractory schizophrenic patients. Method: In this prospective study, 18 treatment-refractory patients with DSM-IV schizophrenia (10 nonsmokers and 8 smokers) were treated with cloza-pine at a target dose of 100 mg h.s. After steady-state conditions of clozapine had been reached, 50 mg/day of fluvoxamine was then added. Plasma levels of clozapine, norclozapine, and clozapine N-oxide were measured prior to fluvoxamine addition and on days 14 and 28 during combined treatment. Side effects and efficacy were monitored with standardized rating instruments. Results: After 14 days of combined treatment, the mean ± SD plasma clozapine level increased 2.3-fold to 432.4 ± 190.9 ng/mL without further elevation on day 28. All patients completed the study without significant adverse side effects. Twelve of the 18 patients achieved plasma clozapine concentrations of at least 350 ng/mL. While plasma norclozapine levels also rose (but to a smaller extent), plasma clozapine N-oxide levels remained unchanged after the add-on therapy. Patients who smoked had 34{\%} lower plasma clozapine concentrations than nonsmokers (NS). Three of the 4 patients who did not reach clozapine plasma levels of at least 300 ng/mL were smokers. Plasma norclozapine/clozapine ratios, especially in smokers, declined significantly with fluvoxamine addition. Conclusion: The addition of fluvoxamine, 50 mg/day, to low-dose clozapine, 100 mg/day, can raise plasma clozapine levels to at least 300 ng/mL in most patients. Only slight dosage adjustments with clozapine may be needed after fluvoxamine coadministration in some patients who smoke. Plasma clozapine levels remained stable after 14 days of fluvoxamine addition. The combined treatment was well tolerated, and clinical improvement was observed in our patients. Further long-term studies with this drug combination are needed to determine its economic impact.",
author = "Lu, {M. L.} and Lane, {H. Y.} and Chen, {K. P.} and Jann, {M. W.} and Su, {M. H.} and Chang, {W. H.}",
year = "2000",
language = "English",
volume = "61",
pages = "594--599",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Fluvoxamine reduces the clozapine dosage needed in refractory schizophrenic patients

AU - Lu, M. L.

AU - Lane, H. Y.

AU - Chen, K. P.

AU - Jann, M. W.

AU - Su, M. H.

AU - Chang, W. H.

PY - 2000

Y1 - 2000

N2 - Background: Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia. Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2. We evaluated the safety and efficacy of fluvoxamine, 50 mg/day, coadministration with clozapine, 100 mg/day, in refractory schizophrenic patients. Method: In this prospective study, 18 treatment-refractory patients with DSM-IV schizophrenia (10 nonsmokers and 8 smokers) were treated with cloza-pine at a target dose of 100 mg h.s. After steady-state conditions of clozapine had been reached, 50 mg/day of fluvoxamine was then added. Plasma levels of clozapine, norclozapine, and clozapine N-oxide were measured prior to fluvoxamine addition and on days 14 and 28 during combined treatment. Side effects and efficacy were monitored with standardized rating instruments. Results: After 14 days of combined treatment, the mean ± SD plasma clozapine level increased 2.3-fold to 432.4 ± 190.9 ng/mL without further elevation on day 28. All patients completed the study without significant adverse side effects. Twelve of the 18 patients achieved plasma clozapine concentrations of at least 350 ng/mL. While plasma norclozapine levels also rose (but to a smaller extent), plasma clozapine N-oxide levels remained unchanged after the add-on therapy. Patients who smoked had 34% lower plasma clozapine concentrations than nonsmokers (NS). Three of the 4 patients who did not reach clozapine plasma levels of at least 300 ng/mL were smokers. Plasma norclozapine/clozapine ratios, especially in smokers, declined significantly with fluvoxamine addition. Conclusion: The addition of fluvoxamine, 50 mg/day, to low-dose clozapine, 100 mg/day, can raise plasma clozapine levels to at least 300 ng/mL in most patients. Only slight dosage adjustments with clozapine may be needed after fluvoxamine coadministration in some patients who smoke. Plasma clozapine levels remained stable after 14 days of fluvoxamine addition. The combined treatment was well tolerated, and clinical improvement was observed in our patients. Further long-term studies with this drug combination are needed to determine its economic impact.

AB - Background: Concomitant fluvoxamine use can potentially reduce the dosage of clozapine needed in treatment-refractory patients with schizophrenia. Previous reports have shown that fluvoxamine can increase plasma clozapine concentrations by inhibition of cytochrome P450 (CYP) 1A2. We evaluated the safety and efficacy of fluvoxamine, 50 mg/day, coadministration with clozapine, 100 mg/day, in refractory schizophrenic patients. Method: In this prospective study, 18 treatment-refractory patients with DSM-IV schizophrenia (10 nonsmokers and 8 smokers) were treated with cloza-pine at a target dose of 100 mg h.s. After steady-state conditions of clozapine had been reached, 50 mg/day of fluvoxamine was then added. Plasma levels of clozapine, norclozapine, and clozapine N-oxide were measured prior to fluvoxamine addition and on days 14 and 28 during combined treatment. Side effects and efficacy were monitored with standardized rating instruments. Results: After 14 days of combined treatment, the mean ± SD plasma clozapine level increased 2.3-fold to 432.4 ± 190.9 ng/mL without further elevation on day 28. All patients completed the study without significant adverse side effects. Twelve of the 18 patients achieved plasma clozapine concentrations of at least 350 ng/mL. While plasma norclozapine levels also rose (but to a smaller extent), plasma clozapine N-oxide levels remained unchanged after the add-on therapy. Patients who smoked had 34% lower plasma clozapine concentrations than nonsmokers (NS). Three of the 4 patients who did not reach clozapine plasma levels of at least 300 ng/mL were smokers. Plasma norclozapine/clozapine ratios, especially in smokers, declined significantly with fluvoxamine addition. Conclusion: The addition of fluvoxamine, 50 mg/day, to low-dose clozapine, 100 mg/day, can raise plasma clozapine levels to at least 300 ng/mL in most patients. Only slight dosage adjustments with clozapine may be needed after fluvoxamine coadministration in some patients who smoke. Plasma clozapine levels remained stable after 14 days of fluvoxamine addition. The combined treatment was well tolerated, and clinical improvement was observed in our patients. Further long-term studies with this drug combination are needed to determine its economic impact.

UR - http://www.scopus.com/inward/record.url?scp=0033861422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033861422&partnerID=8YFLogxK

M3 - Article

C2 - 10982203

AN - SCOPUS:0033861422

VL - 61

SP - 594

EP - 599

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -